Impact of Prior Treatment on the Efficacy of Tabelecleucel for Epstein–Barr Virus-Driven Posttransplant Lymphoproliferative Disease: Subgroup Analysis from the phase 3 Allele Study

Key Points

• Tabelecleucel shows improved efficacy in patients previously treated for Epstein-Barr virus-driven disease, indicating possible benefits of prior therapies.
• In the subgroup analysis, a notable enhancement in treatment response was observed for those receiving tabelecleucel post-therapy.
• This observational analysis addresses the relationship between prior treatments and outcomes using data from the phase 3 Allele study.
• The findings support the idea that treatment strategies may need to be individualized based on prior experiences with therapies.